Long-Term Experience With Apremilast in Psoriatic Arthritis Long-Term Experience With Apremilast in Psoriatic Arthritis
A new analysis shows that apremilast may be safe and effective for longer-term treatment of psoriatic arthritis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Medical News Today: What to know about Xeljanz
This article provides an overview of its uses, how it works, and side effect warnings. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2019 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news
BMS to divest Celgene drugs to speed delayed deal
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene ' s treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 24, 2019 Category: Pharmaceuticals Source Type: news
BMS to divest Celgene drug to speed delayed deal
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene ' s treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 24, 2019 Category: Pharmaceuticals Source Type: news
Interleukin-17 Edges TNF Inhibitor in Psoriatic Arthritis Interleukin-17 Edges TNF Inhibitor in Psoriatic Arthritis
Early outcomes for the combined end point of skin clearance and disease activity in a comparison of biologics can give physicians confidence in the IL-17 inhibitor, SPIRIT-H2H investigators say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Janssen reports top-line Phase 3 results for TREMFYA ® (guselkumab) in adults with active psoriatic arthritis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 14, 2019 Category: Pharmaceuticals Source Type: news
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Data are part of the DISCOVER 1 and 2 program, the first Phase 3 studies to evaluate a selective IL-23 p19 inhibitor in the treatment of psoriatic arthritis
HORSHAM, Pa., June 14, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceut... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, TREMFYA, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2019 Category: Pharmaceuticals Source Type: news
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
INDIANAPOLIS, June 14, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriati... Biopharmaceuticals Eli Lilly, psoriatic arthritis, Taltz, ixekizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2019 Category: Pharmaceuticals Source Type: news
No link between cancer and tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that overall cancer risk is not linked to tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 13, 2019 Category: Cancer & Oncology Source Type: news
Being overweight linked to significantly higher disease severity in psoriatic arthritis
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate significant correlation between body mass index (BMI) and disease severity in psoriatic arthritis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news
Imaging tests help reveal heart risks in patients with psoriatic disease
(Wiley) Patients with psoriasis and psoriatic arthritis -- collectively termed psoriatic disease -- face increased heart risks. A new study published in Arthritis& Rheumatology indicates that ultrasound imaging of the carotid arteries can reveal the extent to which patients' arteries are clogged and also indicate their risk of experiencing future cardiovascular events. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 5, 2019 Category: International Medicine & Public Health Source Type: news
Medical News Today: Can acupuncture help with psoriasis?
Many researchers have looked at the effects of acupuncture on psoriasis and psoriatic arthritis. In this article, we look at how acupuncture can help, what the research says, and how to get acupuncture for psoriasis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 4, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news
Ask Is Psoriatic Arthritis Considered a Disability
Is Psoriatic Arthritis Considered a Disability? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 6, 2019 Category: General Medicine Source Type: news
FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases
Etanercept-ykro (Eticovo) is approved across all eligible indications for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.FDA Approvals (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2019 Category: Rheumatology Tags: Rheumatology News Alert Source Type: news
Medical News Today: What to know about tumor necrosis factor
Tumor necrosis factor is a protein involved in inflammation. Excess tumor necrosis factor (TNF) in the blood has a role in inflammatory conditions, such as forms of arthritis and irritable bowel disease. In this article, we look at TNF, its links with medical conditions, and how to reduce TNF levels. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 1, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news
